LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Inclusion Criteria:

• At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.
• A skin test for grass pollens positive:
• Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.

Exclusion Criteria:

• Have an associated asthma requiring corticosteroid treatment,
• Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,